Jefferies analyst Roger Song upgraded Nektar Therapeutics (NASDAQ: NKTR) from Hold to Buy with a price target of $2.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE